This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, H. Articles by Schimmer, A. D. Search for Related Content PubMed PubMed Citation Articles by Chang, H. Articles by Schimmer, A. D. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Reviews

Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy

¹ Department of Surgery at Shandong Provincial Hospital, School of Medicine, Shandong University, Jinan, Shandong, China and ² The Princess Margaret Hospital and the Ontario Cancer Institute, Toronto, Ontario, Canada

Requests for reprints: Aaron D. Schimmer, Princess Margaret Hospital, Room 9-516, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. Phone: 416-946-2838; Fax: 416-946-6546. E-mail: aaron.schimmer{at}utoronto.ca

Livin, also called melanoma inhibitor of apoptosis protein (IAP) or kidney IAP, is a member of the IAP family of caspase inhibitors that selectively binds the endogenous IAP antagonist SMAC and caspase-3, caspase-7, and caspase-9. As such, Livin inhibits apoptosis, and its overexpression renders malignant cells resistant to chemotherapy. Therefore, inhibitors of Livin could be useful adjuncts to chemotherapy in the treatment of malignancies. This review will discuss Livin as a potential therapeutic target and strategies for its inhibition, including antisense oligonucleotides, small-molecule inhibitors, and immune-mediated approaches. [Mol Cancer Ther 2007;6(1):24–30]

Note: H. Chang is a recipient of fellowship funded from Shandong International Education Exchange Program, P.R. China. A.D. Schimmer is a Canadian Institutes of Health Research Clinician Scientist.

Received 7/28/06; revised 10/ 4/06; accepted 11/20/06.

This article has been cited by other articles:

				H. H. Cheung, S. Plenchette, C. J. Kern, D. J. Mahoney, and R. G. Korneluk The RING Domain of cIAP1 Mediates the Degradation of RING-bearing Inhibitor of Apoptosis Proteins by Distinct Pathways Mol. Biol. Cell, July 1, 2008; 19(7): 2729 - 2740. [Abstract] [Full Text] [PDF]

				J. N. Dynek, S. M. Chan, J. Liu, J. Zha, W. J. Fairbrother, and D. Vucic Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas Cancer Res., May 1, 2008; 68(9): 3124 - 3132. [Abstract] [Full Text] [PDF]